Several studies have provided evidence that enhanced tumor growth inhibition of breast tumors can be achieved by combining Doxorubicin with other agents such as zoledronic acid [33], interleukin-2 [34], TGFβ Inhibitor [35], tetrathiomolybdate [36] as opposed to treating with single agent. The gene discussed is IL2; the disease is breast neoplasm.